1252 related articles for article (PubMed ID: 25500422)
1. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.
Bartelink H; Maingon P; Poortmans P; Weltens C; Fourquet A; Jager J; Schinagl D; Oei B; Rodenhuis C; Horiot JC; Struikmans H; Van Limbergen E; Kirova Y; Elkhuizen P; Bongartz R; Miralbell R; Morgan D; Dubois JB; Remouchamps V; Mirimanoff RO; Collette S; Collette L;
Lancet Oncol; 2015 Jan; 16(1):47-56. PubMed ID: 25500422
[TBL] [Abstract][Full Text] [Related]
2. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial.
Polgár C; Ott OJ; Hildebrandt G; Kauer-Dorner D; Knauerhase H; Major T; Lyczek J; Guinot JL; Dunst J; Miguelez CG; Slampa P; Allgäuer M; Lössl K; Polat B; Kovács G; Fischedick AR; Fietkau R; Resch A; Kulik A; Arribas L; Niehoff P; Guedea F; Schlamann A; Pötter R; Gall C; Uter W; Strnad V;
Lancet Oncol; 2017 Feb; 18(2):259-268. PubMed ID: 28094198
[TBL] [Abstract][Full Text] [Related]
3. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
Vicini FA; Cecchini RS; White JR; Arthur DW; Julian TB; Rabinovitch RA; Kuske RR; Ganz PA; Parda DS; Scheier MF; Winter KA; Paik S; Kuerer HM; Vallow LA; Pierce LJ; Mamounas EP; McCormick B; Costantino JP; Bear HD; Germain I; Gustafson G; Grossheim L; Petersen IA; Hudes RS; Curran WJ; Bryant JL; Wolmark N
Lancet; 2019 Dec; 394(10215):2155-2164. PubMed ID: 31813636
[TBL] [Abstract][Full Text] [Related]
4. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.
Kunkler IH; Williams LJ; Jack WJ; Cameron DA; Dixon JM;
Lancet Oncol; 2015 Mar; 16(3):266-73. PubMed ID: 25637340
[TBL] [Abstract][Full Text] [Related]
5. The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial.
Poortmans PM; Collette L; Bartelink H; Struikmans H; Van den Bogaert WF; Fourquet A; Jager JJ; Hoogenraad W; Müller RP; Dubois JB; Bolla M; Van Der Hulst M; Wárlám-Rodenhuis CC; Pierart M; Horiot JC;
Cancer Radiother; 2008 Nov; 12(6-7):565-70. PubMed ID: 18760649
[TBL] [Abstract][Full Text] [Related]
6. Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial.
Poortmans PM; Collette L; Horiot JC; Van den Bogaert WF; Fourquet A; Kuten A; Noordijk EM; Hoogenraad W; Mirimanoff RO; Pierart M; Van Limbergen E; Bartelink H;
Radiother Oncol; 2009 Jan; 90(1):80-5. PubMed ID: 18707785
[TBL] [Abstract][Full Text] [Related]
7. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial.
Veronesi U; Orecchia R; Maisonneuve P; Viale G; Rotmensz N; Sangalli C; Luini A; Veronesi P; Galimberti V; Zurrida S; Leonardi MC; Lazzari R; Cattani F; Gentilini O; Intra M; Caldarella P; Ballardini B
Lancet Oncol; 2013 Dec; 14(13):1269-77. PubMed ID: 24225155
[TBL] [Abstract][Full Text] [Related]
8. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial.
Vaidya JS; Joseph DJ; Tobias JS; Bulsara M; Wenz F; Saunders C; Alvarado M; Flyger HL; Massarut S; Eiermann W; Keshtgar M; Dewar J; Kraus-Tiefenbacher U; Sütterlin M; Esserman L; Holtveg HM; Roncadin M; Pigorsch S; Metaxas M; Falzon M; Matthews A; Corica T; Williams NR; Baum M
Lancet; 2010 Jul; 376(9735):91-102. PubMed ID: 20570343
[TBL] [Abstract][Full Text] [Related]
9. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.
King MT; Link EK; Whelan TJ; Olivotto IA; Kunkler I; Westenberg AH; Gruber G; Schofield P; Chua BH;
Lancet Oncol; 2020 May; 21(5):685-698. PubMed ID: 32203696
[TBL] [Abstract][Full Text] [Related]
10. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
[TBL] [Abstract][Full Text] [Related]
11. Local recurrence rates in breast cancer patients treated with intraoperative electron-boost radiotherapy versus postoperative external-beam electron-boost irradiation. A sequential intervention study.
Reitsamer R; Peintinger F; Kopp M; Menzel C; Kogelnik HD; Sedlmayer F
Strahlenther Onkol; 2004 Jan; 180(1):38-44. PubMed ID: 14704843
[TBL] [Abstract][Full Text] [Related]
12. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial.
Schäfer R; Strnad V; Polgár C; Uter W; Hildebrandt G; Ott OJ; Kauer-Dorner D; Knauerhase H; Major T; Lyczek J; Guinot JL; Dunst J; Miguelez CG; Slampa P; Allgäuer M; Lössl K; Kovács G; Fischedick AR; Fietkau R; Resch A; Kulik A; Arribas L; Niehoff P; Guedea F; Schlamann A; Gall C; Polat B;
Lancet Oncol; 2018 Jun; 19(6):834-844. PubMed ID: 29695348
[TBL] [Abstract][Full Text] [Related]
13. Ductal carcinoma in situ of the breast with close or focally involved margins following breast-conserving surgery: treatment with reexcision or radiotherapy with increased dosage.
Monteau A; Sigal-Zafrani B; Kirova YM; Fourchotte V; Bollet MA; Vincent-Salomon A; Asselain B; Salmon RJ; Fourquet A
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1021-8. PubMed ID: 19386441
[TBL] [Abstract][Full Text] [Related]
14. Breast irradiation in women with early stage invasive breast cancer following breast conservation surgery. Provincial Breast Disease Site Group.
Whelan TJ; Lada BM; Laukkanen E; Perera FE; Shelley WE; Levine MN
Cancer Prev Control; 1997 Aug; 1(3):228-40. PubMed ID: 9765748
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
[TBL] [Abstract][Full Text] [Related]
16. [Breast-conserving treatment for early invasive lobular breast cancer: 15 years results].
Fodor J; Sulyok Z; Polgár C; Major T; Tóth J; Németh G
Magy Seb; 2001 Aug; 54(4):209-14. PubMed ID: 11550486
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy boost dose-escalation for invasive breast cancer after breast-conserving surgery: 2093 patients treated with a prospective margin-directed policy.
Livi L; Meattini I; Franceschini D; Saieva C; Meacci F; Marrazzo L; Gerlain E; Desideri I; Scotti V; Nori J; Sanchez LJ; Orzalesi L; Bonomo P; Greto D; Bianchi S; Biti G
Radiother Oncol; 2013 Aug; 108(2):273-8. PubMed ID: 23490271
[TBL] [Abstract][Full Text] [Related]
18. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial.
Strnad V; Ott OJ; Hildebrandt G; Kauer-Dorner D; Knauerhase H; Major T; Lyczek J; Guinot JL; Dunst J; Gutierrez Miguelez C; Slampa P; Allgäuer M; Lössl K; Polat B; Kovács G; Fischedick AR; Wendt TG; Fietkau R; Hindemith M; Resch A; Kulik A; Arribas L; Niehoff P; Guedea F; Schlamann A; Pötter R; Gall C; Malzer M; Uter W; Polgár C;
Lancet; 2016 Jan; 387(10015):229-38. PubMed ID: 26494415
[TBL] [Abstract][Full Text] [Related]
19. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.
Whelan TJ; Julian JA; Berrang TS; Kim DH; Germain I; Nichol AM; Akra M; Lavertu S; Germain F; Fyles A; Trotter T; Perera FE; Balkwill S; Chafe S; McGowan T; Muanza T; Beckham WA; Chua BH; Gu CS; Levine MN; Olivotto IA;
Lancet; 2019 Dec; 394(10215):2165-2172. PubMed ID: 31813635
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
